CervoMed Inc. (CRVO) reported a quarterly loss of $0.84 per share, missing the Zacks Consensus Estimate of a loss of $0.68. The company’s revenue for the quarter was $0.32 million, falling short of expectations by 69.24%. The stock has surged 211.5% this year, outperforming the S&P 500.

Despite the recent earnings miss, CervoMed Inc. has a Zacks Rank #3 (Hold), indicating a neutral outlook. Analysts are forecasting a loss of $0.65 per share for the next quarter and -$2.58 for the current fiscal year. The industry rank for Medical – Biomedical and Genetics is in the top 37%.

Investors are eagerly awaiting Cue Biopharma, Inc.’s (CUE) upcoming earnings report, with expectations of a quarterly loss of $0.10 per share. Revenue for the quarter is anticipated to be $2.5 million, a decrease of 25.2% from the previous year. The consensus EPS estimate has remained steady over the past month.

For the latest stock recommendations and insights, Zacks Investment Research offers a free report on the 7 best stocks to buy in the next 30 days. Their proven track record of outperforming the S&P 500 by over 24% annually since 1978 makes them a reliable resource for investors seeking market-beating returns.

Read more at Nasdaq: CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates